A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Completed · Phase 1
Conditions studied: Multiple Myeloma
In brief
The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen. The purpose of the safety/access cohort is to provide continued access to TAK-079 to participants previously enrolled to a TAK-079 parent study and to evaluate the long-term safety profile of TAK-079.
Key facts
- Study ID
- NCT03984097
- Run by
- Takeda
- People needed
- 50
- Starts
- 2019-07-29
- Expected to finish
- 2026-03-25
- Last updated by the study team
- 2026-04-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Alabama Oncology — Birmingham, Alabama, United States
- Pacific Cancer Care — Monterey, California, United States
- American Oncology Partners of Maryland, PA — Bethesda, Maryland, United States
- Columbia University Medical Center — New York, New York, United States
- Levine Cancer Institute — Charlotte, North Carolina, United States
- Good Samaritan Hospital — Cincinnati, Ohio, United States
- Oregon Health & Science University — Portland, Oregon, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.